<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font18 { font-size : 18; } .font20 { font-size : 20; } .font23 { font-size : 23; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font30">the </span>
   <span class="font23">with </span>
   <span class="font20">patients </span>
   <span class="font18">for </span>
   <span class="font15">COVID- </span>
   <span class="font14">SARS-CoV- </span>
   <span class="font14">CLL </span>
   <span class="font14">from </span>
   <span class="font14">chronic </span>
   <span class="font13">treatment </span>
   <span class="font13">lymphocytic </span>
   <span class="font13">are </span>
   <span class="font13">that </span>
   <span class="font12">{background </span>
   <span class="font12">risk </span>
   <span class="font12">not </span>
   <span class="font12">during </span>
   <span class="font12">infection </span>
   <span class="font12">respiratory </span>
   <span class="font12">margin </span>
   <span class="font12">therapy </span>
   <span class="font12">{border-style </span>
   <span class="font11">disease </span>
   <span class="font11">ibrutinib </span>
   <span class="font11">may </span>
   <span class="font11">The </span>
   <span class="font11">px;} </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">Clin </span>
   <span class="font11">symptoms </span>
   <span class="font11">[], </span>
   <span class="font11">can </span>
   <span class="font11">phase </span>
   <span class="font11">COVID-. </span>
   <span class="font11">immune </span>
   <span class="font11">leukemia </span>
   <span class="font11">Blood.;:â€". </span>
   <span class="font11">Cancer </span>
   <span class="font11">Med.;:â€". </span>
   <span class="font11">Oncol.;:â€". </span>
   <span class="font11">[Epub </span>
   <span class="font11">ahead </span>
   <span class="font11">have </span>
   <span class="font11">print]. </span>
   <span class="font11">venetoclax </span>
   <span class="font11">viral </span>
   <span class="font11">Infect </span>
   <span class="font11">cancer </span>
   <span class="font11">clinical </span>
   <span class="font11">evidence </span>
   <span class="font11">should </span>
   <span class="font11">April </span>
   <span class="font11">Engl </span>
   <span class="font11">management </span>
   <span class="font11">received </span>
   <span class="font11">will </span>
   <span class="font11">Lancet </span>
   <span class="font11">Pharmacyclics, </span>
   <span class="font11">RT-PCR </span>
   <span class="font11">higher </span>
   <span class="font11">infections </span>
   <span class="font11">leukemia. </span>
   <span class="font11">other </span>
   <span class="font11">severe </span>
   <span class="font11">than </span>
   <span class="font10">Gilead, </span>
   <span class="font10">Janssen, </span>
   <span class="font10">Patients </span>
   <span class="font10">also </span>
   <span class="font10">honoraria </span>
   <span class="font10">study. </span>
   <span class="font10">this </span>
   <span class="font10">treated </span>
   <span class="font10">who </span>
   <span class="font10">Accessed </span>
   <span class="font10">China. </span>
   <span class="font10">addition, </span>
   <span class="font10">adverse </span>
   <span class="font10">coronavirus </span>
   <span class="font10">factors </span>
   <span class="font10">including </span>
   <span class="font10">its </span>
   <span class="font10">known </span>
   <span class="font10">leukemia: </span>
   <span class="font10">px; </span>
   <span class="font10">research </span>
   <span class="font10">rituximab </span>
   <span class="font10">use </span>
   <span class="font10">when </span>
   <span class="font10">{font-family </span>
   <span class="font10">Abbvie, </span>
   <span class="font10">Blood </span>
   <span class="font10">COVID-, </span>
   <span class="font10">Health </span>
   <span class="font10">after </span>
   <span class="font10">against </span>
   <span class="font10">agents </span>
   <span class="font10">al.Ibrutinib </span>
   <span class="font10">but </span>
   <span class="font10">care </span>
   <span class="font10">follow-up </span>
   <span class="font10">font-size </span>
   <span class="font10">funding </span>
   <span class="font10">general </span>
   <span class="font10">hospital </span>
   <span class="font10">patient </span>
   <span class="font10">patients. </span>
   <span class="font10">relapsed </span>
   <span class="font10">survival </span>
   <span class="font10">through </span>
   <span class="font10">without </span>
   <span class="font10">Care </span>
   <span class="font10">During </span>
   <span class="font10">Leukemia.;:â€". </span>
   <span class="font10">Therapeutics, </span>
   <span class="font10">Wuhan, </span>
   <span class="font10">analysis </span>
   <span class="font10">background </span>
   <span class="font10">based </span>
   <span class="font10">cases </span>
   <span class="font10">diagnosis </span>
   <span class="font10">does </span>
   <span class="font10">double; </span>
   <span class="font10">epidemic </span>
   <span class="font10">following </span>
   <span class="font10">has </span>
   <span class="font10">more </span>
   <span class="font10">mortality </span>
   <span class="font10">nasopharyngeal </span>
   <span class="font10">negative </span>
   <span class="font10">obinutuzumab </span>
   <span class="font10">plus </span>
   <span class="font10">population </span>
   <span class="font10">rate </span>
   <span class="font10">tract </span>
   <span class="font10">treatment. </span>
   <span class="font10">visits </span>
   <span class="font10">&amp;gt; </span>
   <span class="font10">BTK </span>
   <span class="font10">CLL. </span>
   <span class="font10">Coronavirus </span>
   <span class="font10">Dis.;:â€". </span>
   <span class="font10">JAMA.;:â€". </span>
   <span class="font10">Management </span>
   <span class="font10">With </span>
   <span class="font10">acalabrutinib </span>
   <span class="font10">acute </span>
   <span class="font10">al.The </span>
   <span class="font10">anemia </span>
   <span class="font10">anti-leukemic </span>
   <span class="font10">autoimmune </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">case </span>
   <span class="font10">disease, </span>
   <span class="font10">drug </span>
   <span class="font10">effective </span>
   <span class="font10">endemic </span>
   <span class="font10">events </span>
   <span class="font10">first-line </span>
   <span class="font10">free </span>
   <span class="font10">guidelines </span>
   <span class="font10">idelalisib </span>
   <span class="font10">imaging </span>
   <span class="font10">impact </span>
   <span class="font10">infection. </span>
   <span class="font10">influenza </span>
   <span class="font10">inhibitors </span>
   <span class="font10">load </span>
   <span class="font10">lower </span>
   <span class="font10">meta-analysis. </span>
   <span class="font10">morbidity </span>
   <span class="font10">must </span>
   <span class="font10">need </span>
   <span class="font10">non-pharmaceutical </span>
   <span class="font10">nosocomial </span>
   <span class="font10">reducing </span>
   <span class="font10">relapsed/refractory </span>
   <span class="font10">reported </span>
   <span class="font10">results </span>
   <span class="font10">samples </span>
   <span class="font10">seasonal </span>
   <span class="font10">solid; </span>
   <span class="font10">study </span>
   <span class="font10">such </span>
   <span class="font10">swab </span>
   <span class="font10">syndrome </span>
   <span class="font10">targeted </span>
   <span class="font10">tests </span>
   <span class="font10">therapy. </span>
   <span class="font10">those </span>
   <span class="font10">time </span>
   <span class="font10">under </span>
   <span class="font10">until </span>
   <span class="font10">virus </span>
   <span class="font10">while </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">Acerta, </span>
   <span class="font10">Adv.;:â€". </span>
   <span class="font10">Ann </span>
   <span class="font10">Astra </span>
   <span class="font10">CLL, </span>
   <span class="font10">Celgene, </span>
   <span class="font10">Dis.;ciaa. </span>
   <span class="font10">Disease </span>
   <span class="font10">Genentech, </span>
   <span class="font10">However, </span>
   <span class="font10">Lancet.;:â€". </span>
   <span class="font10">Nat </span>
   <span class="font10">RÏ" </span>
   <span class="font10">Verastem, </span>
   <span class="font10">Zeneca, </span>
   <span class="font10">about </span>
   <span class="font10">advanced </span>
   <span class="font10">al.Clinical </span>
   <span class="font10">already </span>
   <span class="font10">anti-CD </span>
   <span class="font10">associated </span>
   <span class="font10">been </span>
   <span class="font10">bold </span>
   <span class="font10">cell </span>
   <span class="font10">characteristics </span>
   <span class="font10">chemoimmunotherapy </span>
   <span class="font10">clinicians </span>
   <span class="font10">compared </span>
   <span class="font10">conditions </span>
   <span class="font10">corticosteroid </span>
   <span class="font10">corticosteroids </span>
   <span class="font10">courier; </span>
   <span class="font10">data </span>
   <span class="font10">days </span>
   <span class="font10">death </span>
   <span class="font10">detected </span>
   <span class="font10">diseases </span>
   <span class="font10">dose </span>
   <span class="font10">due </span>
   <span class="font10">em; </span>
   <span class="font10">even </span>
   <span class="font10">first </span>
   <span class="font10">hemolytic </span>
   <span class="font10">illness </span>
   <span class="font10">immunity </span>
   <span class="font10">infected </span>
   <span class="font10">interventions </span>
   <span class="font10">iwCLL </span>
   <span class="font10">life </span>
   <span class="font10">malignancies </span>
   <span class="font10">monotherapy </span>
   <span class="font10">number </span>
   <span class="font10">one </span>
   <span class="font10">outbreak </span>
   <span class="font10">pandemic </span>
   <span class="font10">prevent </span>
   <span class="font10">previously </span>
   <span class="font10">progression </span>
   <span class="font10">pt;} </span>
   <span class="font10">receiving </span>
   <span class="font10">residual </span>
   <span class="font10">review </span>
   <span class="font10">risks </span>
   <span class="font10">routine </span>
   <span class="font10">safety </span>
   <span class="font10">secondary </span>
   <span class="font10">shedding </span>
   <span class="font10">similar </span>
   <span class="font10">symptoms. </span>
   <span class="font10">test </span>
   <span class="font10">them </span>
   <span class="font10">therapy, </span>
   <span class="font10">these </span>
   <span class="font10">thrombocytopenia </span>
   <span class="font10">transmission </span>
   <span class="font10">trial </span>
   <span class="font10">upper </span>
   <span class="font10">used </span>
   <span class="font10">vaccination </span>
   <span class="font10">versus </span>
   <span class="font10">was </span>
   <span class="font10">which </span>
   <span class="font10">within </span>
  </p>
 </body>
</html>
